BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36358906)

  • 1. Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer.
    Zhang J; Pan S; Han C; Jin H; Sun Q; Du J; Han X
    Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
    Yang X; Tang W; He Y; An H; Wang J
    Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
    Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
    Front Immunol; 2021; 12():749459. PubMed ID: 34603338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
    Zhou Y; Che Y; Fu Z; Zhang H; Wu H
    Front Public Health; 2022; 10():902378. PubMed ID: 35875026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
    Zhang J; Zhang M; Tian Q; Yang J
    Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
    Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
    Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment.
    Zhang J; Jin H; Pan S; Han C; Sun Q; Han X
    Front Immunol; 2023; 14():1073550. PubMed ID: 36814908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
    Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
    Yu B; Luo J; Yang Y; Zhen K; Shen B
    J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
    Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
    BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
    Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
    Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
    Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
    Front Immunol; 2021; 12():650491. PubMed ID: 33968045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
    Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
    J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer.
    Su P; Peng Z; Xu B; Yang B; Jin F
    PeerJ; 2021; 9():e12383. PubMed ID: 34900411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.
    Zhang B; Zhao R; Wang Q; Zhang YJ; Yang L; Yuan ZJ; Yang J; Wang QJ; Yao L
    Adv Ther; 2023 Oct; 40(10):4339-4357. PubMed ID: 37462865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.